Biopharmaceutical benchmarks 2010

Nature Biotechnology

Volumn 28, Issue 9, 2010, Pages 917-924

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABSEAMED; ACRETROPIN; ADALIMUMAB; ARZERRA; BEVACIZUMAB; BIOGRASTIM; BIOPOIN; CANAKINUMAB; CANCER VACCINE; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORIFOLLITROPIN ALFA; ECULIZUMAB; EPORATIO; ERYTHROPOIETIN; ETANERCEPT; EXTAVIA; FERTAVID; FILGRASTIM HEXAL; FILGRASTIM RATIOPHARM; GALSULFASE; HUMAN GROWTH HORMONE; IDURONATE 2 SULFATASE; INFLIXIMAB; INSULIN ASPART; INSULIN GLARGINE; KALBITOR; LIRAGLUTIDE; LUMIZYME; MIPOMERSEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TC 99M; NATALIZUMAB; NIVESTIM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OFATUMUMAB; OPGENRA; PANITUMUMAB; PEGAPTANIB; PERGOVERIS; PREOTACH; PROLIA; PROVENGE; RANIBIZUMAB; RATIOGRASTIM; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT SOMATOMEDIN C; RECOTHROM; REMOVAB; RILONACEPT; RITUXIMAB; ROMIPLOSTIM; SILGARD; SIMPONI; TEVAGRASTIM; TOCILIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VPRIV; WART VIRUS VACCINE; ZARZIO;

BIOTECHNOLOGY; CANCER THERAPY; CROHN DISEASE; DOWNSTREAM PROCESSING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; HUMAN; NEUTROPENIA; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; RHEUMATOID ARTHRITIS; UTERINE CERVIX CANCER;

ANTIBODIES, BISPECIFIC; BENCHMARKING; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; CANCER VACCINES; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, GENERIC; EUROPE; MARKETING; PROTEIN ENGINEERING; UNITED STATES;

EID: 77956690413     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0910-917     Document Type: Review

References (34)

1. Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24, 769-776 (2006).
2. Rader, R. Paucity of biopharma approvals raises alarm. GEN 28, 3-15 (2008).
3. Evers, P. The Future of the Biological Market (Business Insights, March 2010).
4. R&D Pipeline News. Special edition, March 2010. La Merie Business Intelligence, available at www.pipe-linereview.com
5. Scheinecker, C. et al. Tocilizumab. Nat. Rev. Drug Discov. 8, 273-274 (2009).
6. Melmed, G. et al. Certolizumab pegol. Nat. Rev. Drug Discov. 7, 641-642 (2008).
7. Keam, S. Harper, D.M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed). BioDrugs 22, 205-208 (2008).
8. Crum, C., Jones, C., Kirkpatrick, P. Quadrivalent human papillomavirus recombinant vaccine. Nat. Rev. Drug Discov. 5, 629-630 (2006).
9. Schneider, C.K. & Kalinke, U. Towards biosimilar monoclonal antibodies. Nat. Biotechnol. 26, 985-990 (2008).
10. Carlson, B. Biosimilar market fails to meet projections. GEN 29, 43-45 (2009).
11. Mackler, B.F. Biosimilars and follow on branded biolog-ics. GEN 29, 89-92 (2009).
12. The top 10 biosimilars players; positioning performance and SWOT analysis (Business Insights, April 2009) Available at www.globalbusinessinsights.com
13. Westphal, N.J. & Malecki, M.J. Biosimilars 2007-2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake (Decision Resources, October, 2008).
14. Drunker, D.J. et al. Liraglutide. Nat. Rev. Drug Discov. 9, 267-268 (2010).
15. Walsh, G. & Jefferis, R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24, 1241-1252 (2006).
16. Ceaglio, N. et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie 90, 437-449 (2008).
17. Trousdale, R.K. et al. Efficacy of native and hyper-glycosylated follicle-stimulating hormone analogs for promoting fertility in female mice. Fertil. Steril. 91, 265-270 (2009).
18. Zhu, Y. et al. Carbohydrate-remodelled acid α-glucosidase with higher affinity for the cation-independent mannose 6 phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem. J. 389, 619-628 (2005).
19. Zhu, Y. et al. Glycoengineered acid α-glucosidase with improved efficacy at correcting the metabolic aberrations & motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17, 954-963 (2009).
20. Natsume, A. Niwa, R., Satoh, M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Devel. Ther. 3, 7-16 (2009).
21. Hamilton, S.R. et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science. 313, 1441-1443 (2006).
22. DePalma, A. Single use systems make headway with sceptics. GEN 29, 27-31 (2009).
23. Browne, S.M. & Al-Rubeai, M. Selection methods for high producing mammalian cell lines. Trends Biotechnol. 25, 425-432 (2007).
24. Durocher, Y. & Butler, M. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 20, 700-707 (20 09).
25. Liu, C. & Downey, W. Contract manufacturing demands remain strong. GEN 29, 53-59 (2009).
26. DePalma, A. Removing impediments in downstream processing. GEN 29, 135-139 (2009).
27. Davis, M.E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanopar-ticles. Nature 464, 1067-1071 (2010).
28. Hiller, A. Fast growth foreseen for protein therapeutics. GEN 29, 153-155 (2009).
29. Goodman, M. Sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 8, 837 (2009).
30. Sheridan, C. Fresh from the biologic pipeline\-2009. Nat. Biotechnol. 28, 307-310 (2010).
31. Chinese Market for Biopharmaceuticals, Asia Market Information and Development Company, March 2009. Available via www.reportlinker.com
32. Chakraborty, C. & Agoramoorthy, G. A special report on India's biotech scenario: advancement in biopharma-ceutical and healthcare sectors. Biotechnol. Adv. 28, 1-6 (2010).
33. Netterwald, J. Stem cell technologies regenerative medicine. 29, 39-42 (2009).
34. Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035-1041 (2010).